Aridis pharmaceuticals provisionally expecting top line data from ar-301 trial in h2 2021

Aridis pharmaceuticals announces 2019 fourth quarter and year-end financial results and business update.q4 loss per share $0.63.q4 earnings per share estimate $-0.81 -- refinitiv ibes data.aridis pharmaceuticals-pending resolution of coronavirus pandemic, co provisionally expecting interim data from ar-301 trial to be reported in 2h 2020.aridis pharmaceuticals - pending resolution of coronavirus pandemic, is provisionally expecting top line data from ar-301 trial in 2h 2021.
ARDS Ratings Summary
ARDS Quant Ranking